Target intelligence / Profile preview

MAX dimerization protein MGA (MGA) (MGA)

Target
MGA
Molecular classification
Transcription factor, DNA-binding protein
01

Overview

MAX dimerization protein MGA (MGA) is a large transcription factor that plays a pivotal role in the MYC/MAX/MAD network, acting as a primary antagonist to MYC-mediated transcriptional activation. It functions by forming a heterodimer with MAX and binding to specific DNA motifs, such as E-boxes and T-boxes, where it recruits the Polycomb repressive complex 1.6 (PRC1.6) to mediate gene silencing (UniProt Q8IWI9). This regulatory mechanism is essential for controlling cell proliferation and maintaining genomic stability. The MGA gene locus is frequently mutated or deleted in various human malignancies, most notably non-small cell lung cancer (NSCLC) and chronic lymphocytic leukemia (CLL), where its loss leads to the hyperactivation of MYC targets and accelerated tumor growth (Sun et al., 2021; Llabrés et al., 2015). In the field of genomic medicine, the MGA gene locus is considered a target for sequence-specific interventions, such as CRISPR-Cas9, which are utilized in research to investigate the consequences of MGA deficiency or to explore potential therapeutic restoration. Precision in targeting the 'on-target' genomic DNA sequence is critical, as the protein's extensive regulatory network makes it a sensitive node in cellular homeostasis, and off-target effects could lead to unintended oncogenic consequences.

Other names
MAD5MAX gene-associated proteinFunctional domain-containing protein 1MGAD
02

Mechanism of action

MGA acts as a transcriptional repressor by binding to E-box and T-box DNA sequences and recruiting the PRC1.6 complex to silence MYC-target genes (Sun et al., 2021; UniProt Q8IWI9).

03

Biological functions

Transcription regulationTumor suppressionCell cycle controlChromatin remodeling
04

Disease associations

CancerNon-small cell lung cancerChronic lymphocytic leukemiaColorectal cancer
05

Safety considerations

Off-target genomic cleavagePotential for oncogenic transformation if tumor suppressor function is lostDisruption of MYC/MAX/MAD homeostasis
06

Interacting drugs

None currently approved

2 more in the full profile.

07

Biomarkers

MGA mutation statusMGA mRNA expression levelsMYC activity signature

Beyond the preview

Go deeper on MAX dimerization protein MGA (MGA) (MGA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAX dimerization protein MGA (MGA) (MGA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call